CD247 and melanoma: First generation CAR T cells comprising a targeting scFv and chimeric CD3/FcεRIγ have undergone phase I clinical trials for the treatments of ovarian cancer (scFv-FcεRIγ) (Sadelain et al., 2003), refractory follicular lymphoma (scFv-CD3ζ) (Ho et al., 2003), neuroblastoma and melanoma (scFv-CD3ζ) (NCT00085930) (Zhao et al., 2006; Birkholz et al., 2009).